Emtrix market leader in Malaysia with 45% market share
STOCKHOLM , March 12, 2015 - Moberg Pharma AB (STO: MOB) today announced that Emtrix® Fungal Nail Treatment has reached a market leading position in Malaysia with 45% market share* for the full year of 2014. In the fourth quarter of 2014, Emtrix was launched in Malaysia by Moberg Pharma's partner Menarini APAC. Advertising and TV commercials began in November / December and has continued in the new year with continued strong sales.
“We are impressed by Menarini's launch of Emtrix in Malaysia which resulted in a great response from pharmacies as well as consumers. The positive response confirms our view that there is a huge unmet need for a new and better product in the nail fungus category and that the sales potential in the region is significant”, said Peter Wolpert, CEO of Moberg Pharma.
*Source: IMS, 2014
This information is a news update from Moberg Pharma and not a formal press release.
About Moberg Pharma
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with a direct sales and marketing organization in the U.S. and an extensive distributor network in more than 40 countries. The company’s portfolio includes the OTC brands Kerasal®, Jointflex®, Kerasal Nail®, Domeboro®, Vanquish®, and Fergon® as well as Phase II pipeline assets. Kerasal Nail® (Emtrix® and Nalox™ in certain markets outside the U.S.) is the leading product for the treatment of nail disorders in the U.S. and Nordic market. The current portfolio will be supplemented by acquisition and in-licensing of additional products as well as product development with a focus on innovative drug delivery of proven compounds. Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares (OMX: MOB) are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please visit: www.mobergpharma.com .